Mar 19 The rising star in Asia’s genomic profiling platform


CRISPR has been leading the way in the genomic industry, and who will be the next rising star with explosive business opportunities? Bio Asia invited potential candidates to share how they can influence the industry by their technology in Japan during 19 th -20th March. Dr. Shu-Jen Chen, Chief Scientific Officer of ACT Genomics introduced how personal genomic information can be transformed into guidance for cancer treatment selection through their know-how, which attracted investors’ attention.

Image title